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Abstract
The international community has committed to ending the epidemics of
HIV/AIDS, tuberculosis, malaria, and neglected tropical infections by 2030, and
this bold stance deserves universal support. In this paper, we discuss whether
this ambitious goal is achievable for HIV/AIDS and what is needed to further
accelerate progress. The joint United Nations Program on HIV/AIDS (UNAIDS)
90-90-90 targets and the related strategy are built upon currently available
health technologies that can diagnose HIV infection and suppress viral
replication in all people with HIV. Nonetheless, there is much work to be done in
ensuring equitable access to these HIV services for key populations and those
who remain outside the rims of the traditional health services. Identifying a cure
and a preventive vaccine would further help accelerate progress in ending the
epidemic. Other disease control programmes could learn from the response to
the HIV/AIDS epidemic.
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Introduction
On 1 January 2016, we entered the new era of the Sustainable 
Development Goals (SDGs) that will guide the development 
agenda of the international community for the next 15 years up to 
2030. Within these goals, the international community has commit-
ted to a bold agenda (SDG.3.4) of ending the epidemics of HIV/
AIDS, tuberculosis, malaria, and neglected tropical infections by 
20301. This vision deserves widespread support. In this paper, we 
discuss whether this ambitious goal is achievable for HIV/AIDS 
by 2030 and what is further needed to accelerate progress towards 
ending the epidemic.
Achievements and challenges in HIV/AIDS up to 2015
The Millennium Development Goals (MDGs) were conceived 
in 2000 with MDG 6 aiming to halt and reverse the spread of 
HIV/AIDS by 2015 (similar targets were set for tuberculosis and 
malaria). For HIV/AIDS, this goal was achieved. From 2001 to 
2013, the annual incidence of HIV infections decreased by 38%, 
from 3.4 million in 2001 to 2.1 million in 20132. From 2002 to 
2013, the annual incidence of HIV infections in children decreased 
by 58%, with 240,000 new infections in 2013 compared with 
580,000 in 20022. In some regions of the world, mother-to-child 
transmission of HIV has been virtually eliminated2. AIDS-related 
deaths also decreased by 35% between 2005 (when the highest 
number of deaths was recorded) and 20132.
Despite this laudable progress, HIV/AIDS remains a major public 
health threat. In 2015, at the end of the MDG era, there were still 
an estimated 2.1 million new HIV infections worldwide, adding 
up to a total of 36.7 million people living with HIV/AIDS, and 
there were 1.1 million deaths3. Enormous challenges continue. 
Although knowledge of HIV status amongst people living with 
HIV is higher than before, more than half do not know they are 
infected with HIV4. In many countries, there are key populations in 
whom HIV incidence and AIDS-related mortality are much higher 
than in the general population: adolescent girls, sex workers, men 
who have sex with men (MSM), transgender people, people who 
inject drugs, prisoners, and migrants4. Structural and legal barriers 
impede technical progress. For example, same-sex sexual acts are 
criminalised in 78 countries and are punishable by death in seven4. 
Sex work is illegal and criminalised in 116 countries and, almost 
everywhere, illegality and criminalisation envelope persons who 
inject drugs4. These barriers make it difficult for some of the key 
populations to access HIV services. Indeed, in some countries in 
Central Asia, Eastern Europe, the Middle East, and North, West, 
and Central Africa with limited access to services for key popu-
lations, the number of new HIV infections is rising4. In addition, 
reaching populations affected by conflict and humanitarian crises 
and migrants (internal and cross-border) is a challenge now and will 
be in the years to come.
The scale up of antiretroviral therapy (ART) has been one of the 
major public health success stories of our time, with 17 million 
people accessing ART by the end of 2015 – 2 million more than 
the 15 million target set by the United Nations General Assembly 
in 20113. Global coverage of ART reached 46% at the end of 
2015, with the greatest gains made in the world’s worst-affected 
regions of East and Southern Africa. South Africa alone had nearly 
3.4 million people on treatment. However, coverage globally is not 
uniform. Eastern Europe and Central Asia, for example, have seen 
little expansion in ART scale up in the last few years. Treatment 
coverage is also often worse among men compared with women, 
with men frequently initiating treatment late and adhering poorly 
to medication3.
Finally, for HIV/AIDS, there has been a significant funding gap 
relative to the resources needed to fully address the epidemic, and 
the gap is growing. This problem is acute in some low- and middle-
income countries where external financing is reducing and domes-
tic resources do not match needs2,4.
The response to HIV/AIDS and ending the epidemic
Given the size of the problem and on-going challenges with HIV/
AIDS, what makes us think that the goal of ending the AIDS 
epidemic can be achieved? First, there is compelling evidence that 
certain biomedical interventions can significantly reduce new HIV 
infections and AIDS-related mortality. The key measures are the 
diagnosis of HIV infection and the sustained provision of ART to 
all those diagnosed with HIV. Treatment for HIV, especially when 
given immediately after diagnosis irrespective of CD4 count or 
World Health Organization (WHO) clinical stage, substantially 
reduces the risk of illness and death in the individual, and this has 
been shown conclusively in randomised controlled trials5,6. The 
benefits of immediate ART also go beyond those for individual 
patients. Immediate ART reduces the risk of sexual transmission 
of HIV, this benefit having been demonstrated not only in clinical 
trials but also in the real world setting7,8. Immediate ART reduces 
the risk of acquiring herpes simplex virus type-2 infection9, 
decreases the risk of tuberculosis10, provides concurrent treatment 
for hepatitis B infection, and obviates the current problem of poor 
retention in pre-ART care11. Option B+, the current recommended 
strategy for preventing mother-to-child transmission, has immediate 
ART at its core and, by offering lifelong treatment to HIV-infected 
pregnant and breastfeeding mothers regardless of CD4 cell count or 
WHO clinical stage, has significant benefits for HIV transmission 
prevention and maternal health12.
This body of knowledge prompted the joint United Nations 
Program on HIV/AIDS (UNAIDS) to release new 90-90-90 
treatment targets for HIV13. These targets specify that by 2020, 
90% of individuals living with HIV will know their HIV status, 
90% of people with diagnosed HIV infection will receive sustained 
ART, and 90% of those on ART will be virally suppressed. If this 
three-part strategy is achieved, nearly three-quarters of all people 
living with HIV will be on treatment and virally suppressed by 
2020. Modelling studies suggest that this outcome will enable 
the world to end the AIDS epidemic by 2030, defined as a 90% 
reduction in both incidence of HIV and AIDS-related mortality13.
Knowledge of HIV status
The first key measure is knowledge of HIV status. The development 
of inexpensive, sensitive, specific, rapid, and simple-to-use diag-
nostic tests has allowed HIV testing to be scaled up, decentralised, 
and undertaken when necessary by non-laboratory-based personnel. 
Currently available third-generation rapid tests are able to detect 
HIV antibodies approximately 21 days after exposure; research 
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is also on-going to reduce false negative tests during this three-
week window period14. While the greatest diagnostic yields come 
from provider-initiated testing and counselling at health facilities, 
the need to increase case detection at the population level and to 
diagnose HIV earlier in the course of infection has led to a broad 
array of community-based approaches targeting asymptomatic 
people outside of health facilities, including home-based, mobile, 
workplace, school, self, and campaign-oriented testing2,15. Self-
testing is emerging as a useful and potentially supplementary way 
to increase the proportion of people who know their HIV status16. 
Point-of-care HIV testing, using oral fluid rapid tests and car-
ried out by peers, has also been successfully introduced at social 
venues in Brazil for key hard-to-reach populations such as trans-
gender people, MSM, and commercial sex workers, and this has 
resulted in improved access to HIV testing17. With all of these 
methods, though, it is crucial that there is good linkage to ART, 
and innovative approaches (such as additionally offering home 
initiation of treatment) need to be pilot tested and scaled up16.
Safe and effective ART with the response closely monitored
The second key measure is provision of safe and effective ART. 
Treatment has come a long way since combination therapy was first 
shown to be effective in reducing morbidity and mortality in patients 
with advanced HIV infection in developed countries in the mid-
1990s18. Costs have plummeted and the current WHO-recommended 
first-line regimen of tenofovir-lamivudine (emtricitabine)-efavirenz 
is effective, safe, and non-toxic and is taken as a single pill once a 
day19. Further work being done on a lowered dose of efavirenz and 
improved safety of a novel tenofovir prodrug holds promise that this 
single-dose, one-pill-a-day regimen will become largely devoid of 
side effects and will require little or no laboratory monitoring in the 
future20,21. The development of safe, effective, and non-toxic medica-
tion paved the way for the WHO to recommend that ART should be 
offered to all persons living with HIV regardless of clinical stage or 
CD4 cell count22,23. Monthly or less frequent dosing by using long-
acting injectable therapeutics (“depo-drugs”) could further improve 
adherence and treatment outcomes in the future24.
Monitoring the response to ART is crucial. Some countries with 
limited resources, such as Malawi, have managed through a public 
health approach to monitor the numbers of people living with HIV 
who initiate ART and, of those, the numbers who are alive and 
retained in care, are dead, are lost to follow-up, have discontinued 
therapy, or have transferred from one ART clinic to another25. While 
programmatic treatment outcomes are important for assessing 
effectiveness and for planning the resources needed on the ground, 
the measurement of viral load is key for assessing whether ART is 
effective and whether HIV disease is progressing or drug resistance 
is developing2. Current viral load technologies are laboratory based 
and costly, so there is an urgent need to invest in, develop, and 
roll out low-cost, point-of-care viral load tests that can be used to 
monitor ART at all levels of the health system to determine whether 
drug adherence is poor (and therefore correctable) or whether a 
switch in treatment regimen is needed. At the Durban XXI Interna-
tional AIDS Conference in July 2016, it was clear that several new 
point-of-care viral load tests have already been assessed and 
should be ready soon to be deployed in the field – this is where 
investments need to be made with viral load testing replacing CD4 
cell count technology.
Other HIV prevention measures
While scale up and implementation of HIV testing and ART 
initiation for those HIV infected in different epidemic settings 
are essential to the global strategy, it is well recognised that 
a combination response with other well-proven interventions 
(pre-exposure prophylaxis [PrEP] with antiretroviral drugs, 
voluntary medical male circumcision, condom promotion, behav-
iour change programmes, opioid drug substitution, needle and 
syringe exchange programmes, and outreach programmes for 
MSM and sex workers) that depend on country and context will be 
needed to achieve maximum benefit2,26.
For PrEP, the science is now clear that a co-formulation of 
oral tenofovir and emtricitabine significantly reduces the risk of 
HIV infection among non-HIV-infected persons at high risk of 
acquiring infection27. Randomised controlled trials and open-
label extension studies have shown the efficacy of this approach 
in MSM28,29, heterosexual men and women in HIV-discordant 
relationships30,31, and people who inject drugs32. The studies that 
have shown no benefit of PrEP have identified poor adherence 
to medication as the main culprit33. Expanding access to PrEP is 
therefore not only sound public health policy but also a human 
rights imperative, and this strong addition to the HIV prevention 
arsenal has been recognised in the recent WHO Consolidated 
Guidance on treating and preventing HIV22,23.
Voluntary male medical circumcision is another proven HIV 
prevention strategy that was tested in three randomised trials 
between 2005 and 2007 in South Africa, Kenya, and Uganda34–36. 
The results showed that male medical circumcision reduced HIV 
acquisition in men by about 60%. Other benefits of this surgical 
approach to HIV prevention include a decrease in incidence of 
herpes simplex virus type-2 and human papillomavirus infection37. 
Since 2008, the uptake of voluntary medical male circumcision 
has increased rapidly, with more than 10 million procedures 
performed by September 201526.
The contribution of different interventions will vary depending on 
the epidemic setting2. For example, in generalised epidemics, the 
scale up of ART, especially immediate start of treatment, could 
contribute the most to a reduction in new infections, followed by 
condoms, PrEP, voluntary male medical circumcision, outreach to 
sex workers, and behaviour change communications. In epidemics 
driven by injecting drug use, the major contributors to a reduction 
in new infections could come from opioid drug substitution, needle 
and syringe exchange programmes, and the strategic use of ART. 
As countries move towards epidemic control targets, innovative 
and more efficient service delivery models that include improved 
diagnostic tools and longer-acting antiretroviral drugs will likely 
further accelerate progress towards ending the epidemic.
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Addressing structural, legal, and social barriers
Several structural factors are recognised as being key to the HIV/
AIDS response, and these need to be addressed to maximise the 
chances of achieving the target goal by 20302. For example, the 
completion of secondary education reduces vulnerability to HIV 
infection, with the effects particularly seen in girls38. Violence pre-
vention and HIV programming can have potential benefits, espe-
cially when integrated into community empowerment schemes that 
embrace microfinance support. Community mobilisation interven-
tions can help to change behaviour associated with high risk of HIV 
infection. The many laws, policies, and practices that stigmatise and 
discriminate against people living with HIV and key populations 
must be challenged and removed. Civil society and activism, the 
anchor sheet for years of the HIV/AIDS response, is under threat 
through restrictive laws and funding cuts, so the global HIV com-
munity must show solidarity with civil society and reaffirm its place 
in the HIV/AIDS response. Young people are those most affected 
by the HIV epidemic, and countries and initiatives worldwide need 
to recruit and train the younger generation and use their language 
and their tools (social media and encounter apps) to leverage the 
fight against HIV/AIDS. Innovations in science and technology are 
more likely to be accepted and taken up by the younger generation 
who now need to take on a leadership role and carry the torch for 
ending the HIV epidemic by 2030.
Is there a cure or vaccine to end the AIDS epidemic?
The success of ART has led to the consideration of whether a 
cure for AIDS might be possible. Although ART causes complete 
or near-complete inhibition of HIV replication, the virus persists 
in long-lived infected resting T cells, which contain integrated, 
transcriptionally latent HIV DNA, and these serve as a reservoir 
for on-going infection39. Cure in HIV/AIDS is usually defined as 
sterilising (all latent HIV-infected cells are eliminated) or 
functional (latent HIV persists but viraema is very low or absent 
without the use of ART). The only reported case of a sterilising 
cure is the Berlin patient, an HIV-infected man given a bone mar-
row transplant from a naturally HIV-resistant donor for acute mye-
loid leukaemia39. While an interesting observation, such an invasive 
intervention could never at present be widely implemented. The 
focus has therefore been on the possibility of a functional cure.
The first report of a functional cure was that of an infant born to 
an HIV-infected woman who received ART within 30 hours of 
birth (the Mississippi baby), with the child having an undetectable 
viral load after ART was discontinued at the age of 18 months40. 
This was followed by speculation that very early treatment might 
prevent the formation of latent reservoirs for HIV, at least in infants 
with an immature immune system. Unfortunately, recent evidence 
of viral rebound in the Mississippi child has shattered hopes for 
this approach41. At present, no cure for HIV is in sight, although 
the research continues. Ultimately, getting rid of HIV from latent 
reservoirs will need a combination approach both for activation of 
the virus and for clearance, a biomedical strategy known as “shock 
and kill”42.
Some have argued that the only guarantee of a sustained end to the 
AIDS epidemic will be a combination of non-vaccine prevention 
methods and the deployment of a safe and effective HIV vaccine43. 
Ever since HIV was discovered as the cause of AIDS in 1983–1984, 
intensive work has been undertaken to develop a preventive vaccine. 
Yet, to date, only three vaccines have completed clinical efficacy 
trials. The first two candidate vaccines failed their efficacy trials44, 
while the third vaccine (RV144) showed modest efficacy at 31% in 
preventing acquisition of HIV infection45. Despite these setbacks 
and the inherent difficulties in developing an effective HIV vaccine, 
the science continues with optimism that theory and empiricism 
will ultimately coalesce for a good end result46.
Conclusion
We believe that the goal of ending the HIV/AIDS epidemic by 2030 
is achievable and should gather momentum. The WHO’s “3 by 
5” strategy, aiming to provide ART for 3 million people by 2005, 
was thought to be wildly over-ambitious and unrealistic by some. 
However, in reality, it inspired concerted international action and 
huge progress, leading to momentum that ultimately resulted 
in 17 million people receiving ART by 20152. The current bold 
ambitious target for HIV/AIDS is similarly needed to inspire, 
energise, and mobilise communities.
Modelling studies suggest that meeting the 90-90-90 targets 
using current health technologies will enable the goal of ending 
HIV/AIDS by 2030 to be achieved, even without a therapeutic 
means of cure or a preventive vaccine13. We have come to this 
point because i) the diagnosis of HIV is based on rapid, easy-to-use 
diagnostic tests that are truly point of care, allowing decentrali-
sation and task sharing and therefore wide coverage, ii) ART is 
now a single, once-a-day pill that is effective, safe, and relatively 
non-toxic and hence can be used in asymptomatic persons with 
or without HIV to both treat HIV and prevent the transmission of 
infection, and iii) there has been significant engagement by the 
community affected by HIV resulting in dramatically reduced 
drug pricing and increased access, significant international donor 
interest in the form of the GFATM (the Global Fund to Fight 
AIDS, Tuberculosis, and Malaria) and PEPFAR (the US President’s 
Emergency Plan for AIDS Relief), and successful programme 
delivery in many settings.
Diagnosing the millions of people who do not know that they 
have HIV and starting and retaining those people on ART 
are daunting prospects and will require increased focus and 
efficiency including strong political will, scale up of human 
resources, logistic capacity, better-functioning health systems, 
innovations in service delivery including community- and patient-
driven initiatives, and additional financial resources. Importantly, 
finding practical ways of reaching those who lie outside the rims 
of the traditional health services, “the how to deliver”, will need 
focused attention. This includes populations affected by conflict 
and humanitarian crises.
Over the past 30 years, funding for the HIV/AIDS response in 
low- and middle-income countries has risen from almost nothing 
to $19 billion per annum, although it is estimated that this needs 
to rise further to $36 billion per annum to achieve the UN goal of 
ending the AIDS epidemic by 20302. In many settings, though, the 
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reality is that less than half of the resources are spent on ensuring 
access to early treatment and the price tag to optimise treatment 
coverage may well be within the current funding envelope. It is 
our opinion that a substantial part of HIV/AIDS funding, including 
that from the Global Fund and PEPFAR, is spent on non-evidence-
based interventions, and this has to change with monitoring and 
evaluation ensuring that resources are well utilised. Efficient use of 
funds also means controlling corruption and preventing the devia-
tion of resources to activities other than HIV and health system 
strengthening.
In summary, in the last decade, the HIV/AIDS community has 
shown itself capable of rising to a plethora of challenges; in the 
absence of complacency, we should be able to accelerate progress 
over the next two decades and end the AIDS epidemic.
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